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Summary
Background Rapid declines in malaria prevalence, cases, and deaths have been achieved globally during the past 
15 years because of improved access to ﬁ rst-line treatment and vector control. We aimed to assess the intervention 
coverage needed to achieve further gains over the next 15 years.
Methods We used a mathematical model of the transmission of Plasmodium falciparum malaria to explore the potential 
eﬀ ect on case incidence and malaria mortality rates from 2015 to 2030 of ﬁ ve diﬀ erent intervention scenarios: 
remaining at the intervention coverage levels of 2011–13 (Sustain), for which coverage comprises vector control and 
access to treatment; two scenarios of increased coverage to 80% (Accelerate 1) and 90% (Accelerate 2), with a switch 
from quinine to injectable artesunate for management of severe disease and seasonal malaria chemoprevention 
where recommended for both Accelerate scenarios, and rectal artesunate for pre-referral treatment at the community 
level added to Accelerate 2; a near-term innovation scenario (Innovate), which included longer-lasting insecticidal 
nets and expansion of seasonal malaria chemoprevention; and a reduction in coverage to 2006–08 levels (Reverse). 
We did the model simulations at the ﬁ rst administrative level (ie, state or province) for the 80 countries with sustained 
stable malaria transmission in 2010, accounting for variations in baseline endemicity, seasonality in transmission, 
vector species, and existing intervention coverage. To calculate the cases and deaths averted, we compared the total 
number of each under the ﬁ ve scenarios between 2015 and 2030 with the predicted number in 2015, accounting for 
population growth.
Findings With an increase to 80% coverage, we predicted a reduction in case incidence of 21% (95% credible intervals 
[CrI] 19–29) and a reduction in mortality rates of 40% (27–61) by 2030 compared with 2015 levels. Acceleration to 90% 
coverage and expansion of treatment at the community level was predicted to reduce case incidence by 59% (Crl 56–64) 
and mortality rates by 74% (67–82); with additional near-term innovation, incidence was predicted to decline by 74% 
(70–77) and mortality rates by 81% (76–87). These scenarios were predicted to lead to local elimination in 13 countries 
under the Accelerate 1 scenario, 20 under Accelerate 2, and 22 under Innovate by 2030, reducing the proportion of the 
population living in at-risk areas by 36% if elimination is deﬁ ned at the ﬁ rst administrative unit. However, failing to 
maintain coverage levels of 2011–13 is predicted to raise case incidence by 76% (Crl 71–80) and mortality rates by 46% 
(39–51) by 2020.
Interpretation Our ﬁ ndings show that decreases in malaria transmission and burden can be accelerated over the next 
15 years if the coverage of key interventions is increased.
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Introduction
Rapid declines in malaria have been achieved globally 
during the past 15 years because of improved access to 
treatment and vector control. The estimated proportion 
of children younger than 5 years at risk from malaria 
who sleep under a bednet in sub-Saharan Africa has 
increased from less than 2% in 2005 to 68% (95% CI 
61–72) in 2015,1 and the estimated proportion of patients 
with conﬁ rmed Plasmodium falciparum malaria receiving 
appropriate treatment (artemisinin combination 
therapy) increased from less than 1% in 2005 to 16% 
(range 12–22) across countries in 2014.1,2 This increase 
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resulted in an estimated reduction in the annual global 
incidence of malaria of 37% and in malaria-speciﬁ c 
mortality rates of 60% between 2000 and 2015.3 Much of 
this progress has been in Africa, where transmission of 
malaria is most intense. Elsewhere, substantial progress 
has been made towards local elimination, with four 
countries (Armenia, Morocco, Turkmenistan, and 
United Arab Emirates) certiﬁ ed as malaria-free, nine 
entering the prevention of reintroduction phase, and 
20 progressing to the pre-elimination or elimination 
phases.1
These gains can be attributed to the renewed political 
commitment to malaria control and elimination 
stimulated by the Millennium Development Goals and 
supported through global and national resource 
mobilisation. These eﬀ orts were aided by the ﬁ rst 
Global Malaria Action Plan, which was published in 
2008 to align stakeholders’ eﬀ orts to support endemic 
countries in reducing the burden of malaria.4 The 
Global Technical Strategy for Malaria was developed by 
WHO to provide a vision and goals for malaria for 
2016–30 along with a technical strategy for achieving 
these goals.3 This strategy is complemented by the 
Action and Investment to defeat Malaria strategy from 
the Roll Back Malaria partnership, which guides the 
implementation and ﬁ nancing of activities to reduce 
and eliminate malaria.5
Here we describe the mathematical modelling 
undertaken as part of the development of the Global 
Technical Strategy to assess the feasibility of the proposed 
burden and elimination goals and the intervention 
coverage needed to achieve these goals, focusing on the 
80 countries with persisting stable transmission of 
P falciparum malaria.
Methods
Transmission model
We used a mathematical model of the transmission of 
P falciparum to estimate the eﬀ ect of diﬀ erent 
intervention strategies.6,7 In the model, individuals begin 
life susceptible to P falciparum infection and are exposed 
to infectious bites at a rate that depends on local mosquito 
density and infectivity. Newborn infants passively acquire 
maternal immunity, which decays in the ﬁ rst 6 months 
of life. After exposure, individuals are susceptible to 
clinical disease6 and severe disease8 and are at risk of 
death. As they get older, the risk of developing disease 
declines through acquisition of naturally acquired 
immunity due to continued exposure. During 
adolescence, parasitaemia levels fall so that a high 
proportion of asymptomatic infections become sub-
micro scopic. Full mosquito-population dynamics were 
included in the model to capture the eﬀ ects of vector 
control in preventing transmission, killing adult female 
mosquitoes, and the resulting reduction in egg-laying. 
The model was ﬁ tted to data for the relations between 
rainfall, mosquito abundance, entomological inoculation 
rate (the rate at which people receive infectious bites), 
parasite prevalence, clinical disease incidence, severe 
disease incidence, and death.6–9 A range of interventions 
are included7,9–11 (appendix).
Baseline endemicity
We restricted our analysis to the 80 countries in which 
P falciparum malaria was stably endemic (deﬁ ned as 
having non-zero prevalence) in 2010.12 Estimates of the 
spatial distribution of the human population were taken 
from the Global Rural-Urban Mapping Project13 and 
overlaid with estimates of parasite prevalence in children 
Research in context
Evidence before this study
The previous global strategy for malaria outlined in the Global 
Malaria Action Plan (2008) set the goals of a 75% reduction in 
malaria incidence and near-zero deaths by 2015. Substantial 
progress has been made towards these goals, with an estimated 
37% reduction in case incidence and 60% reduction in mortality 
rates between 2000 and 2015. New goals have now been set as 
part of WHO’s Global Technical Strategy for Malaria 2016–30, 
endorsed by the World Health Assembly in May, 2015. To inform 
this goal setting, we reviewed the National Strategic Plans from 
all malaria-endemic countries and undertook a country-by-
country review of previous trends in malaria cases for the 
59 countries with suﬃ  ciently complete and consistent data. We 
searched the scientiﬁ c literature using PubMed with the search 
terms “projection OR mathematical model” AND “malaria OR 
falciparum OR plasmodium”, for English-language articles 
published between Jan 1, 2000, and Feb 6, 2015, but did not 
identify any modelling studies estimating the potential 
trajectories of Plasmodium falciparum malaria at a global level.
Added value of this study
Our modelled scenarios provide an indication of the potential 
additional beneﬁ t of accelerating strategies for prevention and 
treatment of P falciparum malaria over the next 15 years. These 
provide a consistent estimate across all 80 countries with 
persisting endemic malaria in 2010 and further provide a link 
between the necessary coverage and probable eﬀ ect that 
cannot be ascertained from National Strategic Plans or case 
trends alone. The results from this exercise form part of the 
evidence used to set the goals for the WHO Global Technical 
Strategy for Malaria 2016–30.
Implications of all the available evidence
The evidence suggests that substantial further gains can be 
made by increasing existing methods to reduce the burden of 
malaria and move countries towards malaria elimination over 
the next 15 years. It also shows that further progress can be 
made with near-term innovations. 
See Online for appendix
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aged 2–10 years in 2010 at a resolution of 1 km.12 We used 
these estimates to calculate the population-weighted 
mean parasite prevalence in each ﬁ rst administrative 
level (ie, province or state). We used UN world population 
projections to capture substantial population growth for 
rural and urban populations.14
Transmission intensity and vector species
We calibrated the baseline transmission intensity in the 
model in each ﬁ rst administrative unit with endemic 
transmission to match the estimated parasite prevalence 
separately for urban and rural areas (appendix). We made 
no further adjustments for countries in Africa, except 
Botswana, Madagascar, Namibia, and South Africa, for 
which more reliable reported case data were available. For 
these four countries and countries outside Africa, we 
scaled the mosquito density (retaining the spatial 
distribution at the ﬁ rst administrative unit) so that the 
estimates of uncomplicated malaria in 2010 matched those 
reported in the WHO 2013 World Malaria Report (WMR).15
To capture the global variation in Anopheles species, we 
combined estimates of the spatial distribution of vector 
species with estimates of their bionomics (appendix).16–19 
 We accounted for seasonal variation in transmission in 
Africa based on rainfall patterns in each location.20 Since 
the relation between vector species abundance and 
rainfall is more complex outside Africa, we assumed a 
single seasonal proﬁ le in south Asia and a non-seasonal 
proﬁ le elsewhere.
Existing intervention coverage
Data about country-speciﬁ c coverage of interventions 
from 2000 to 2013 were taken from the WMR 2013,15 with 
a few exceptions. For countries in Africa, we used the 
estimates of use of long-lasting insecticidal nets from 
2000 to 2013 from a model combining data from the 
Demographic Health Survey, Malaria Indicator Survey, 
and Malaria Indicator Cluster Surveys with 
manufacturers’ delivery data and countries’ distribution 
reports.21 For countries outside Africa, we used reports of 
coverage from National Malaria Control Programmes 
from 2000 to 2012, as reported in the WMR 2013.15 Our 
model incorporates insecticide decay in long-lasting 
insecticidal nets and wear-and-tear over time. For all 
countries, coverage of indoor residual spraying from 
2000 to 2012 was based on data from National Malaria 
Control Programmes as reported in the WMR 201315 and 
calculated as the number of people protected by indoor 
residual spraying each year divided by the population at 
risk.15 For countries in Africa, antimalarial and 
artemisinin combination therapy and treatments 
received in the public or private sectors were based on 
modelled estimates of coverage from the Demographic 
Health Survey and the Malaria Indicator Cluster 
Surveys.22 For countries outside Africa, we used data 
from the WMR 2013.15 These coverage levels show 
treatment received in the public sector only. We used 
estimates from the WMR 2013 of the proportion of 
patients with malaria seeking care in the public and 
private sectors and mortality rates, and, for cases outside 
Africa, assumed that the treatment rate given in the 
private sector was half that given in the public sector.
Future scenarios
We simulated the potential eﬀ ect of ﬁ ve intervention 
scenarios (panel). The ﬁ rst (Sustain) assumes that 
interventions remain at their 2011–13 coverage levels and 
provides a baseline for comparison with other scenarios. 
We considered two acceleration scenarios (Accelerate 1 
and Accelerate 2) in which coverage of currently 
recommended interventions (vector control and seasonal 
malaria chemoprevention) and access to ﬁ rst-line 
Panel: Summary of intervention scenarios 
Scenario 1: Sustain
Continue long-lasting insecticidal nets, indoor residual spraying, and access to treatment 
levels as in 2011–13.
Scenario 2: Accelerate 1
Vector control (modelled as long-lasting insecticidal nets) increased from 2013 levels to 
80% access from 2015 to 2020 (or retained at present levels if higher), and maintained 
through continuous redistribution, replacing nets every 3 years. 
Access to ﬁ rst-line treatment with artemisinin combination therapy in the public sector 
rose to 80% between 2015 and 2020 and maintained thereafter.
Access to ﬁ rst-line treatment with artemisinin combination therapy in the communities, 
as part of integrated community case management and in the private sector, increased to 
50% between 2015 and 2025, with scale-up to 75% by 2030.
Seasonal malaria chemoprevention in areas in which it is currently recommended for 
children aged 6 months to 5 years with sulfadoxine–pyrimethamine plus amodiaquine 
scaled up to 80% coverage between 2015 and 2020.
Switch from quinine to injectable artesunate for severe disease between 2015 and 2020 
for all patients with malaria admitted to hospital. 
Scenario 3: Accelerate 2
Accelerate 1 scenario plus:
Access to long-lasting insecticidal nets rose to 90% from 2020 to 2025, with continuous 
distribution such that individual nets are replaced every 2 years from 2025. 
Access to ﬁ rst-line treatment with artemisinin combination therapy in the public sector 
increased to 90% between 2015 and 2020, and maintained thereafter.
Rectal artesunate scaled up to 50% coverage by 2025 and to 75% by 2030, and assumed 
to reduce fatalities by 50% in patients with severe disease but not admitted to hospital.
Increase coverage of seasonal malaria chemoprevention to 95% from 2020 to 2025.
Scenario 4: Innovate (additional near-term methods)
Accelerate 2 scenario plus:
Longer-lasting nets with 4-year half-life from insecticide decay and wear and tear, 
from 2020 onwards.
Switch seasonal malaria chemoprevention drug to a compound with similar duration of 
protection that can also be implemented in areas of east Africa that are resistant to 
sulfadoxine–pyrimethamine.
Increase age range of seasonal malaria chemoprevention up to 10 years from 2020 onwards.
Reverse
Coverage of interventions declines to levels reported in 2006–08.
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treatment is increased to either 80% (Accelerate 1) or 90% 
(Accelerate 2) and case management is improved through 
a switch to injectable artesunate (from quinine) for 
management of severe disease. For Accelerate 2, we 
additionally intro duced rectal artesunate for the pre-
referral treatment of severe malaria at the community 
level. In the fourth scenario (Innovate), we included near-
term innovations, including longer-lasting insecticidal 
nets and expansion of seasonal malaria chemoprevention 
with an alternative compound in seasonal areas of Africa 
(where at least 60% of the annual rainfall occurs in the 
peak 3 months of the year) with high levels of 
sulphadoxine–pyrimethamine resistance (where seasonal 
malaria chemo prevention is not currently recommended) 
plus expansion in the age range to children aged from 
3 months up to 10 years. For all four scenarios we 
assumed no loss of eﬀ ect due to drug or insecticide 
resistance. In a ﬁ fth scenario (Reverse) we considered the 
eﬀ ect of a scale-back in intervention coverage to levels 
recorded in 2006–08 (appendix). This scenario could 
represent a loss of funding, or mimic the potential eﬀ ect 
of reduced susceptibility of pyrethroid-based vector 
control.23
For all model runs we assumed that interventions 
remained at their 2011–13 coverage levels (depending 
on the data source) up to 2015. We then ran the 
simulation model at the ﬁ rst administrative unit for 
each intervention scenario from 2015 to 2030. To 
calculate the cases and deaths averted we compared the 
total number of cases or deaths under each scenario 
between 2015 and 2030 with the predicted number in 
2015, accounting for human population growth. We 
calculated the population at risk at both national and 
subnational levels (appendix). Local elimination was 
established on the basis of 50 stochastic realisations 
and deﬁ ned as elimination in at least 50% of the 
realisations. For all scenarios, we did a comprehensive 
uncertainty analysis in a Bayesian framework with 
results presented as approximate Bayesian 95% credible 
intervals (CrI).
Role of the funding source
Members of the Bill & Melinda Gates Foundation, UK 
Department for International Development, and US 
Agency for International Development provided input into 
the development of the scenarios through their formal 
roles on the Global Technical Strategy and Global Malaria 
Action Plan 2 scientiﬁ c committees. The funders had no 
role in data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Figure 1 shows the predicted trajectories of the Sustain, 
Accelerate, and Innovate scenarios. With Sustain, we 
predicted a rise in case incidence by 28% (95% CrI 23–32) 
and mortality rates by 11% (1–20) by 2030 from 2015 
levels (table). This predicted change was due to 
population-level loss of immunity induced by increased 
intervention coverage (appendix). 
Under the Accelerate 1 scenario (present interventions 
scaled up to meet the universal coverage target of 80%) we 
predicted that case incidence would be reduced from 2015 
levels by 21% (19–29) by 2030 (table). Similarly, we 
predicted that the incidence of mortality would be reduced 
from 2015 levels by 40% (27–61) by 2030 (table). The faster 
decline in mortality rates compared with case incidence 
was due to the additional eﬀ ect of prompt ﬁ rst-line 
treatment and improved management of cases of severe 
disease. Overall, we estimated that this scenario would 
avert 1·7 billion cases (95% CrI 1·2 billion–2·3 billion) and 
6·3 million deaths (3·2 million–8·7 million) deaths over 
the 15-year period (a mean of 110 million fewer cases 
[80 million–150 million] and 420 000 fewer deaths 
[210 000–580 000] per year) compared with the Sustain 
scenario.
Under the Accelerate 2 scenario, we predicted that case 
incidence would be reduced from 2015 levels by 59% 
(95% CrI 56–64) and mortality by 74% (67–82) by 2030 
(table), averting a mean of 2·9 billion cases (95% CrI 
2·0 billion–3·8 billion) and 10·4 million deaths 
(4·2 million–14·4 million) over the 15-year period 
(a mean of 190 million fewer cases [95% CrI 
140 million–250 million] and 690 000 fewer deaths 
[280 000–960 000] per year) compared with Sustain. With 
Figure 1: Predicted trajectories of Plasmodium falciparum malaria under a range of scenarios* from 2000 to 2030
Graphs show (A) the incidence of uncomplicated malaria and (B) mortality rates from malaria under the Sustain, 
Accelerate, and Innovate scenarios; (C) the incidence of uncomplicated malaria and (D) mortality from malaria 
under the Reverse scenario compared with the Sustain scenario. Incidence of uncomplicated malaria mortality are 
for all ages. Shaded bands around the mean projections show 95% credible intervals. *See panel for speciﬁ cs of the 
scenarios.
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Innovate, further progress can be made, with cases 
reduced by an estimated 74% (95% CrI 70–77) and deaths 
by 81% (76–87) by 2030, averting an estimated 3·30 billion 
cases (95% CrI 2·37 billion–4·33 billion) and 11·5 million 
deaths (4·6 million–16·0 million) over the 15-year period 
(a mean of 220 million fewer cases [95% CrI 
160 million–290 million] and 760 000 fewer deaths 
[300 000–1 070 000] per year).
With the Reverse scenario, we predicted a rise in case 
incidence and mortality rates above those estimated for 
the year 2000, in which coverage for both interventions 
(ie, longer-lasting insecticidal nets and treatment rates) 
was low (ﬁ gure 1). This rise was due to loss of naturally 
acquired immunity as transmission declines, such that 
loss of coverage leads to rebound epidemics in many 
settings. Under this negative scenario we estimated an 
increase in case incidence of 76% (95% CrI 71–80) and in 
mortality of 46% (39–51%) from 2015 to 2020 (the peak 
time of the rebound). This rise translates to an estimated 
521 000 additional deaths (95% CrI 216 000–725 000) in 
2020 compared with 2015.
The predicted eﬀ ect that can be achieved with the 
scenarios substantially varied between countries. The 
variation depended on both the intrinsic potential for 
transmission (which made it more diﬃ  cult to reduce 
transmission in high-burden areas) and the extent to 
which interventions were already at high coverage before 
2013. Overall, we predicted that 33 of 80 countries would 
achieve more than a 90% reduction in incidence—or an 
incidence of less than one case per 1000 individuals per 
year—under Accelerate 1; an additional nine countries 
were predicted to achieve this goal under Accelerate 2 
(ﬁ gure 2).
18 of these countries were predicted to be below the 
pre-elimination threshold of one case per 1000 individuals 
per year in 2015. Under Accelerate 1, we estimated that 
13 countries would achieve local elimination by 2030, 
and 20 under Accelerate 2. With the Innovate scenario, 
we predicted that 22 countries would locally eliminate 
P falciparum by 2030, and that the burden in an additional 
18 countries would fall below the pre-elimination 
threshold (ﬁ gure 2).
Acceleration of coverage could substantially aﬀ ect the 
global map of malaria endemicity. Under Accelerate 2, 
we predicted that large areas of South America, and 
southeast and south Asia, would become free of endemic 
transmission by 2030, along with lower transmission 
achieved in some areas of Africa (ﬁ gure 3). The videos 
show the predicted change in global distribution of 
P falciparum malaria from 2015 to 2030 under each 
scenario.
Figure 4 shows how the global population living in 
at-risk areas would decrease as a result of the 
Accelerate 1, Accelerate 2, and Innovate scenarios from 
2015 to 2030. Under Accelerate 2, if elimination is 
deﬁ ned at the country level, the proportion living in 
areas that have eliminated P falciparum malaria by 2030 
would be 6%. However, if elimination is deﬁ ned at the 
level of the ﬁ rst administrative unit, then 36% would 
live in areas that have eliminated the disease. Also 
under Accelerate 2, we estimated that the population 
living in areas with persisting transmission (deﬁ ned at 
the level of the ﬁ rst administrative unit) would decrease 
from 1·44 billion in 2015 to 1·23 billion in 2030—a 15% 
reduction despite a 25% increase in populations of 
areas that were malaria endemic in 2010.
Percentage change in case incidence (95% approximate credible 
intervals)
Percentage change in mortality rates (95% approximate credible 
intervals)
2020 2025 2030 2020 2025 2030
Sustain 21% (18 to 23) 27% (23 to 30) 28% (23 to 32) 11% (7 to 16) 12% (5 to 19) 11% (1 to 20)
Accelerate 1 –19% (–22 to –17) –23% (–28 to –21) –21% (–29 to –19) –30% (–43 to –20) –36% (–51 to –24) –40% (–61 to –27)
Accelerate 2 –43% (–46 to –42) –62% (–65 to –59) –59% (–64 to –56) –55% (–63 to –48) –70% (–77 to –62) –74% (–82 to –67)
Innovate –48% (–51 to –46) –77% (–79 to –75) –74% (–77 to –70) –57% (–65 to –51) –79% (–85 to –73) –81% (–87 to –76)
Positive values show an increase compared with 2015, and negative values show a decrease compared with 2015. Changes in incidence and mortality are per unit population 
and therefore do not show population growth. *See panel for speciﬁ cs of the scenarios. 
Table: Eﬀ ect of four scenarios* on the predicted global incidence of malaria cases and deaths by year, compared with 2015
Figure 2: Estimated number of countries meeting progress milestones under the Sustain, Accelerate, and 
Innovate scenarios*
Graphs show the number of countries achieving high-burden reduction, pre-elimination levels, and local 
elimination by the years 2020, 2025, and 2030. Elimination is deﬁ ned as zero locally acquired cases in that year. 
Pre-elimination is deﬁ ned as countries that do not eliminate but reach levels of less than one case per 1000 people 
per year. High-burden reduction is deﬁ ned as countries that have not reached pre-elimination but reduce case 
incidence by at least 90% relative to 2015. *See panel for speciﬁ cs of the scenarios.
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Figure 3: Projected 
geographical distribution of 
Plasmodium falciparum 
malaria under the 
Accelerate 2 scenario 
between 2015 and 2030
Graphs show projected 
distribution for the years 2015 
(A), 2020 (B), 2025 (C), and 
2030 (D). Red changing to pink 
shows a gradient of reducing 
case incidence. Purple areas are 
those in which local elimination 
is predicted. See videos for 
projections by year with all 
scenarios. See panel for 
speciﬁ cs of the scenarios.
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Discussion
Despite the gains made in reducing malaria transmission 
during the past 15 years, the burden of malaria remains 
high. Our results show that over the next 15 years 
additional substantial reductions could be achieved, 
provided malaria control interventions are scaled up 
towards the universal coverage targets set out in the 
original global malaria action plan.4 In particular, if scale-
up is accelerated so that 90% of the population in at-risk 
areas has access to vector control, chemoprevention, and 
appropriate treatment, we predict a marked global 
decline in malaria transmission that will result in a 
substantial decrease in case incidence and mortality 
rates, with a particularly large eﬀ ect in the high-burden 
countries.
Our results also show the contribution that scaling up 
of coverage of currently recommended interventions 
could make to malaria elimination. Although timescales 
for elimination are diﬃ  cult to predict, our results suggest 
that several areas in South America and Asia could 
eliminate malaria by 2030. Our modelled scenarios 
assumed that a high proportion of cases are identiﬁ ed 
and promptly treated, which is essential to prevent 
resurgent epidemics. Thus investment in information 
systems and surveillance will be essential.
Our results further show the fragility of malaria 
control. If intervention coverage remains at the levels 
achieved from 2011 to 2013, we predict a moderate rise in 
malaria incidence and mortality. This rise is due to the 
changing immunity proﬁ le in the population, with 
people born after interventions have been scaled up 
being exposed more slowly and hence acquiring their 
ﬁ rst and subsequent cases at an older age. If intervention 
coverage falls, or if interventions become less eﬀ ective 
(which could occur, for example, if levels of resistance to 
the pyrethroids used in insecticide-treated nets continue 
to increase23), our simulations show the potential for 
resurgent epidemics, as noted in settings in which 
malaria prevention was removed before elimination had 
been achieved.24 Thus, adequate intervention coverage 
must be maintained while transmission continues.
Although substantial progress can be made with 
current interventions, innovation to develop new 
products and strategies is urgently needed to accelerate 
further towards malaria elimination. Such innovation is 
particularly necessary in areas with intense transmission, 
in which high levels of intervention coverage are 
insuﬃ  cient to lead to elimination or where substantial 
residual transmission happens because of a combination 
of human and vector behaviour.25 Such innovation is also 
needed to eﬀ ectively manage or contain resistance to 
insecticides and drugs.23,26
One limitation of our study is that the same scenario is 
applied ubiquitously across all countries with persisting 
stable malaria transmission. Although this method 
enables the magnitude of achievable gains to be 
estimated, tailored strategies are needed for diﬀ erent 
local contexts and to make best use of the ﬁ nite resources 
available. These strategies will need strengthening of 
information systems so that appropriate intervention 
programmes can be designed, monitored, and adapted as 
malaria transmission declines. Some countries might be 
able to proceed more rapidly than assumed here, 
although in others with hard-to-access populations or 
instability due to behavioural or civil unrest, progress 
might be slower. Additionally, new methods and 
strategies are likely to become available (including focally 
targeted strategies for low transmission settings) and 
hence could accelerate the trends modelled here. Our 
results suggest that to achieve malaria eradication, 
investment in such methods is essential. 
A second limitation is that our model was developed 
for P falciparum only. Although trends in Plasmodium vivax 
cases tend to track those for P falciparum in many 
countries, the former has proven more diﬃ  cult to 
eliminate because of the hidden reservoir of parasites 
(hypnozoites) that can remain in the liver for months to 
years.27 Several models for P vivax are now being 
developed to ﬁ ll this gap.28–30 Third, the strategies were 
applied at the ﬁ rst administrative unit with no 
connectivity. Finer spatial granularity and movement 
between locations is needed to guide individual country 
decisions and regional prioritisation, particularly as 
transmission declines and the spatial distribution of 
malaria becomes more heterogeneous. Finally, many 
factors not captured here might aﬀ ect malaria 
transmission, including changing health systems, 
housing, education, climate, and land use.
In summary, reductions in malaria transmission and 
burden can be accelerated over the next 15 years if the 
level of coverage of current interventions is increased. 
However, to further accelerate eﬀ orts towards elimin-
ation, new transformative methods will need to be 
developed. Essentially, the momentum achieved up to 
Figure 4: Changing global population at risk of Plasmodium falciparum malaria under a range of scenarios 
between 2015 and 2030
Graphs show the percentage of the population residing in areas that are malaria endemic before 2015 who are 
predicted to live in areas in which malaria has been locally eliminated in subsequent years. (A) Elimination is 
deﬁ ned at the country level. (B) Elimination is deﬁ ned at the ﬁ rst administrative level.
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now should be continued, to reduce malaria burden and 
move rapidly towards the elimination, and ultimately 
eradication, of malaria.
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